Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Mol Pharm. 2017 Apr 12;14(5):1782–1789. doi: 10.1021/acs.molpharmaceut.7b00056

Figure 4.

Figure 4

Quantification of PET regions-of-interest for several tissues over time. (A) The tracer remained in circulation over the length of the study for all three groups, while liver and spleen uptake were similar in all study groups. (B) Tumor uptake of 64Cu-DOTA-ipilimumab was higher in A549 and H460 at both 24 and 48 h p.i. (C) Injection of excess unlabeled ipilimumab prior to the tracer resulted in decreased tumor uptake at all timepoints in A549 tumors. *p < 0.05.